All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CTL-002
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Vesalius Biocapital III
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 10, 2020
Details:
CatalYm’s lead molecule CTL-002 was specifically designed to neutralize a tumor-produced protein called GDF-15. CTL-002 addresses three of the tumor’s immune suppressive mechanisms all involving the inhibitory effect of GDF-15 on the immunostimulatory LFA-1/ICAM-1 interaction.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMA401
Therapeutic Area: Oncology Product Name: IMA401
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
IMA401 is the first product candidate from Immatics’ TCR Bispecifics pipeline. The IMA401 target, an HLA-A*02-bound peptide derived both from MAGEA4 and MAGEA8, shows >5-fold higher target peptide levels on cancer cells than target peptide derived from MAGEA4.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibody-targeted Amanitin-Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Heidelberg Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 22, 2020
Details:
ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT® cell line expression platform, incl over process development till GMP manufacturing of the mAb intermediates of Heidelberg Pharma’s ATAC molecules for cancer indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMA204
Therapeutic Area: Oncology Product Name: IMA204
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Two affinity-enhanced TCR candidates designed using Immatics’ proprietary XCEPTOR™ platform demonstrates high specificity and potency; one of the candidates shows full functionality also in CD4+ T cells without requirement for a CD8 co-receptor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Humanized T-cell therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $78.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 06, 2020
Details:
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TUB-010
Therapeutic Area: Oncology Product Name: TUB-010
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: BioMedPartners
Deal Size: $12.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 21, 2020
Details:
The funds will be used to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RevCAR-T 1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Intellia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 20, 2020
Details:
The companies will conduct joint research to combine GEMoaB’s proprietary RevCAR technology platform with Intellia’s proprietary genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies to treat cancers and inflammatory diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T cell immunotherapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Arya Sciences Acquisition Corp
Deal Size: $252.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 17, 2020
Details:
Deal aims at identifying cancer targets and developing the right TCRs for immunotherapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT211
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020
Details:
The data for BNT211 reports Claudin 6 as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a new RNA vaccine promoting the amplification of CAR-T cells in vivo.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
